BridgeBio Pharma, Inc. Cash Divested from Deconsolidation
BridgeBio Pharma, Inc. (BBIO) reported Cash Divested from Deconsolidation of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Cash
us-gaap:CashDivestedFromDeconsolidation · last filed 2026-02-24
- BridgeBio Pharma, Inc. cash divested from deconsolidation for the quarter ending 2025-12-31 was $0.00.
- BridgeBio Pharma, Inc. cash divested from deconsolidation for the quarter ending 2024-12-31 was $0.00.
- BridgeBio Pharma, Inc. cash divested from deconsolidation for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BridgeBio Pharma, Inc. cash divested from deconsolidation for fiscal 2024 was $140.00K, a 72.17% decline from fiscal 2023.
- BridgeBio Pharma, Inc. cash divested from deconsolidation for fiscal 2023 was $503.00K.
- BridgeBio Pharma, Inc. cash divested from deconsolidation for fiscal 2018 was $2.86M.
| Period end | Cash Divested from Deconsolidation 3 month | Cash Divested from Deconsolidation 9 month | Cash Divested from Deconsolidation 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-29 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $140.00K 10-K · filed 2026-02-24 | |
| 2024-09-30 | $140.00K 10-Q · filed 2025-10-29 | ||
| 2023-12-31 | $503.00K 10-K · filed 2026-02-24 | ||
| 2018-12-31 | $2.86M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |